A study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-muscle Invasive Bladder Cancer
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Subjects must have histologically confirmed, non-muscle invasive urothelial (transitional cell) carcinoma with carcinoma in situ (CIS) (with or without papillary disease). 2) Histological confirmation should occur within 60 days prior to first dose of study treatment. 3) Predominant histologic component (>50%) must be urothelial (transitional cell) carcinoma.

You may not be eligible for this study if the following are true:

  • 1) Current or prior history of muscle-invasive urothelial carcinoma (ie, T2, T3, or T4 disease) or metastatic disease. 2) Nodal or metastatic disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) done within 3 months prior to the start of study treatment. 3) Concomitant upper tract urothelial carcinoma as noted on CT or MRI urogram with contrast of abdomen/pelvis performed within 3 months prior to the start of study treatment.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.